Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Levy

Showing results (71-80 of 78) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 78 results.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|January 5, 2002
Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinaseK W Ward, J W Prokscht, L M Azzaranot, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 1, 1997
Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivoB J Votta, M A Levy, A Badger, et al.
Clinical Epigenetics|January 7, 2021
DNA methylation epi-signature is associated with two molecularly and phenotypically distinct clinical subtypes of Phelan-McDermid syndromeL C Schenkel, E Aref-Eshghi, K Rooney, et al.
Journal of Medicinal Chemistry|October 10, 1998
Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimeticS K Thompson, W W Smith, B Zhao, et al.
Journal of Medicinal Chemistry|September 11, 1998
Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin KR W Marquis, D S Yamashita, Y Ru, et al.
Bioorganic & Medicinal Chemistry|June 3, 1999
Potent dipeptidylketone inhibitors of the cysteine protease cathepsin KR W Marquis, Y Ru, D S Yamashita, et al.
The Journal of Biological Chemistry|May 24, 2000
Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionalityD Lee, S A Long, J L Adams, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 1998
Design of potent and selective human cathepsin K inhibitors that span the active siteS K Thompson, S M Halbert, M J Bossard, et al.
Pageof 8

Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|January 5, 2002
Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinaseK W Ward, J W Prokscht, L M Azzaranot, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 1, 1997
Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivoB J Votta, M A Levy, A Badger, et al.
Clinical Epigenetics|January 7, 2021
DNA methylation epi-signature is associated with two molecularly and phenotypically distinct clinical subtypes of Phelan-McDermid syndromeL C Schenkel, E Aref-Eshghi, K Rooney, et al.
Journal of Medicinal Chemistry|October 10, 1998
Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimeticS K Thompson, W W Smith, B Zhao, et al.
Journal of Medicinal Chemistry|September 11, 1998
Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin KR W Marquis, D S Yamashita, Y Ru, et al.
Bioorganic & Medicinal Chemistry|June 3, 1999
Potent dipeptidylketone inhibitors of the cysteine protease cathepsin KR W Marquis, Y Ru, D S Yamashita, et al.
The Journal of Biological Chemistry|May 24, 2000
Potent and selective nonpeptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionalityD Lee, S A Long, J L Adams, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 1998
Design of potent and selective human cathepsin K inhibitors that span the active siteS K Thompson, S M Halbert, M J Bossard, et al.
Pageof 8